SlidesetOncologyExposure-Response Analysis of Lee 1810, a Lead Spectinamide Antibiotic in Mycobacterium tuberculosis Infected Mice- Santosh WaghView Slideset
SlidesetOncologyImproved efficacy of a cofactor-independent InhA inhibitor revealed by the C3HeB/ FeJ mouse model- Gregory RobertsonView Slideset
SlidesetOncologyHigh dose rifampicin for the treatment of TB meningitis: a dose finding study- Rob Aarnoutse, PharmD, PhDView Slideset
SlidesetOncologyOtotoxicity is associated with exposure to kanamycin and capreomycin in the treatment of multidrug-resistant tuberculosis- Mohammed AslshaerView Slideset
SlidesetOncologyA Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents- Alexander Berg, PharmD, PhD, FCPView Slideset
SlidesetOncologyPharmacokinetics of rifampicin in African children - Evaluation of the new WHO dosing guidelines- Paolo DentiView Slideset
SlidesetOncologyQuantitative Analysis of MGIT Time to Positivity Using a Two-Part Longitudinal Model in Patients with Pulmonary Tuberculosis: A Meta-Analysis of 11 Clinical Studies Including 30 Unique Regimens- Nastya Kassir, PharmD, PhD, FCPView Slideset
SlidesetOncologyPrediction of increase in time-to-positivity after higher doses of rifampicin based on pharmacokinetic-pharmacodynamic modelling- Robin SvenssonView Slideset
SlidesetOncologyInfluence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis- Kristina BigelowView Slideset
